Cortland Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Cortland Associates’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$14K	–	53
2017 Q3	$14K	Hold	10,000	–	–	﹤0.01%	47
2017 Q2	$15K	Hold	10,000	–	–	﹤0.01%	46
2017 Q1	$26K	Hold	10,000	–	–	0.01%	50
2016 Q4	$26K	Sell	10,000 -5,000	-33%	-$14.4K	0.01%	52
2016 Q3	$46K	Buy	+15,000	New	+$46.7K	0.01%	51
2015 Q4	–	Sell	-40,000	Closed	-$183K	–	45
2015 Q3	$183K	Hold	40,000	–	–	0.04%	38
2015 Q2	$208K	Hold	40,000	–	–	0.04%	35
2015 Q1	$250K	Buy	40,000 +5,000	+14%	+$28.9K	0.05%	32
2014 Q4	$220K	Sell	35,000 -31,000	-47%	-$189K	0.05%	33
2014 Q3	$401K	Buy	66,000 +3,000	+5%	+$20.5K	0.1%	22
2014 Q2	$415K	Buy	63,000 +34,000	+117%	+$383K	0.08%	21
2014 Q1	$690K	Buy	29,000 +8,000	+38%	+$116K	0.14%	20
2013 Q4	$224K	Buy	+21,000	New	+$232K	0.05%	32

Other funds holding ECYT

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cortland Associates's ECYT Position: Q4 2017 in Review

Cortland Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 10,000 shares — an estimated $14K sold.

Cortland Associates first reported a position in ECYT in Q4 2013 and held it in 13 quarters. The position peaked at $690K in Q1 2014. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

Cortland Associates reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Cortland Associates sold 10,000 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $14K.
Cortland Associates first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 13 quarters.
Cortland Associates's Endocyte, Inc. Common Stock position peaked at $690K in Q1 2014.
71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on Cortland Associates's 13F filing for Q4 2017, filed 24 Jan 2018.